Pharmaceutical

Podcast: Adaptive logistics in a changing clinical land...

Adaptive logistics are vital for clinical trials, but there are challenges in na...

Stealth faces another hurdle as FDA delays decision on ...

The FDA rejected the company’s initial NDA in 2021, citing the lack of an adequa...

Disc raises $225.5m as it eyes approval of rare skin di...

Disc Medicine finalised the pivotal Phase III trial design of bitopertin in eryt...

FDA adds boxed warning to multiple sclerosis drugs afte...

The FDA reported that six patients died after being injected with Teva’s Copaxon...

Emcure Pharmaceuticals opens new R&D centre in Gujarat,...

Emcure Pharmaceuticals has opened its new formulation research and development (...

AbbVie and Neomorph link on oncology/immunology glue de...

AbbVie and Neomorph are set to enter a partnership and option-to-license agreeme...

Pharmaceutical Technology Excellence Awards 2024 – Winn...

The Pharmaceutical Technology Excellence Awards winners have been announced! Dow...

Magazine: The biggest challenges clinical trials will f...

The year ahead in clinical trials looks set to be one that is challenged and inf...

Biogen’s higher dose Spinraza under review by US and EU...

Biogen’s applications for the higher dose regimen of spinal muscular atrophy (SM...

Bladder cancer: Shaping the future of global clinical t...

A new report dives into the evolving clinical trial landscape and transformative...

FDA grants ODD status to Zai Lab’s lung cancer treatment

The FDA has granted orphan drug designation (ODD) to Zai Lab’s ZL-1310, aimed at...

Emergent seeking to reverse fortunes and become a major...

Emergent Biosolutions (Gaithersburg, US) has purchased US and Canadian rights to...

J&Js Lazcluze/Rybrevant combination obtains European ap...

The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-o...

Junshi partners LEO Pharma for toripalimab distribution...

Junshi Biosciences and TopAlliance are set to enter a collaboration with LEO Pha...

Active Pharmaceutical Ingredients and Intermediates for...

Discover the top Active Pharmaceutical Ingredients and Intermediates companies. ...

CEPI provides $6.2m to push first mRNA-based Rift Valle...

Afrigen Biologics has secured a $6.2m grant from CEPI to develop the first mRNA-...